Axa’s ANI Pharmaceuticals ANIP Stock Holding History

Axa’s Portfolio ANIP Stock Details ANIP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-6,100	Closed	-$344K	–	1426
2014 Q4	$344K	Buy	+6,100	New	+$269K	﹤0.01%	1177

Other funds holding ANIP

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return

BIM

Bogle Investment Management Newton Lower Falls, Massachusetts $63M AUM 51.97% 1-Year Est. Return

Axa's ANIP Position: Q1 2015 in Review

Axa sold out of ANI Pharmaceuticals (ANIP) in Q1 2015, closing a stake of 6,100 shares — an estimated $344K sold.

Axa first reported a position in ANIP in Q4 2014 and held it in 1 quarter. The position peaked at $344K in Q4 2014. 126 funds tracked by Wall St. Rank hold ANIP as of Q1 2015.

Axa reported no remaining ANI Pharmaceuticals position as of Q1 2015 after selling out during the quarter.
Axa sold 6,100 ANI Pharmaceuticals shares in Q1 2015, an estimated $344K.
Axa first reported a position in ANI Pharmaceuticals in Q4 2014 and held it in 1 quarter.
Axa's ANI Pharmaceuticals position peaked at $344K in Q4 2014.
126 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q1 2015.

Based on Axa's 13F filing for Q1 2015, filed 13 May 2015.